APA (7th ed.) Citation

Inoue, Y., Yano, Y., Kushida, S., Hirohata, S., Yoon, S., Yasutomi, E., . . . Kodama, Y. Higher Absolute Lymphocyte Counts and Lower Des‐γ‐Carboxyprothrombin Levels After Treatment Initiation Are Associated With the Clinical Efficacy of Tremelimumab Plus Durvalumab Combination Therapy for Hepatocellular Carcinoma. Wiley.

Chicago Style (17th ed.) Citation

Inoue, Yuta, et al. Higher Absolute Lymphocyte Counts and Lower Des‐γ‐Carboxyprothrombin Levels After Treatment Initiation Are Associated With the Clinical Efficacy of Tremelimumab Plus Durvalumab Combination Therapy for Hepatocellular Carcinoma. Wiley.

MLA (9th ed.) Citation

Inoue, Yuta, et al. Higher Absolute Lymphocyte Counts and Lower Des‐γ‐Carboxyprothrombin Levels After Treatment Initiation Are Associated With the Clinical Efficacy of Tremelimumab Plus Durvalumab Combination Therapy for Hepatocellular Carcinoma. Wiley.